T-cell Based Immunotherapy for of Melanoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00937625|
Recruitment Status : Completed
First Posted : July 13, 2009
Last Update Posted : August 18, 2015
The aim of this study is to investigate the toxicity and clinical response of therapy with tumor infiltrating lymphocytes as treatment for advanced melanoma.
Patient will receive a single treatment consisting of conditioning chemotherapy for seven days (cyclophosphamide for two days and fludarabine for five days), intravenous infusion of high number of in vitro expanded tumor infiltrating lymphocytes followed by two weeks with daily low-dose interleukine-2. Patients will be evaluated for toxicity, tumor response, and immune response.
After the first 6 patients the treatment with IL-2 has been changed to include higher doses of IL-2 (see intervention)
|Condition or disease||Intervention/treatment||Phase|
|Melanoma||Biological: cyclophosphamide, fludarabine, T-cells, Interleukin-2||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||31 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||T-cell Based Immunotherapy for Treatment of Patients With Disseminated Melanoma.|
|Study Start Date :||June 2009|
|Actual Primary Completion Date :||January 2015|
|Actual Study Completion Date :||January 2015|
Biological: cyclophosphamide, fludarabine, T-cells, Interleukin-2
- Cyclophosphamide, Sendoxan®, Baxter A/S
- Fludarabine, Fludara®, Bayer Shering
- Interleukin-2, Proleukin®, Chiron B.V.
- toxicity [ Time Frame: week 0 to 20 ]
- immune response [ Time Frame: week 0 to 20 ]
- tumor response [ Time Frame: week 8 and every 3rd week until progression ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00937625
|Department of Oncology, Copenhagen University Hospital, Herlev|
|Herlev, Denmark, 2730|
|Study Director:||Inge Marie Svane, Professor, MD||Department of Oncology, Copenhagen University Hospital, Herlev, Herlev Ringvej 75, DK-2730 Herlev, Denmark|
|Principal Investigator:||Rikke Andersen, MD||Center for Cancer Immune Therapy, department of Oncology, Herlev Hospital, Denmark|